Late Breaking Science

LATE BREAKING SCIENCE

INTERNATIONAL STROKE CONFERENCE 2016

(revised 1/22/16)

Plenary Session I

LB1. Main Results of the Insulin Resistance Intervention After Stroke (IRIS) Trial

Walter N. Kernan, Yale School of Medicine, New Haven, CT

Embargoed for 11:20 a.m. PT, Wednesday, Feb. 17, 2016 / Presented: 11:20 a.m. PT (Hall K)

LB2. Finding Atrial Fibrillation In Stroke Patients - A Multicenter Randomised Evaluation Of Enhanced And Prolonged Holter Monitoring (Find-AFrandomised- Trial)

Rolf Wachter, University of Goettingen, Göttingen, Germany

Embargoed for 11:20 a.m. PT, Wednesday, Feb. 17, 2016 / Presented: 11:32 a.m. PT (Hall K)

LB25. Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis:

Initial and Five-year Results of the ACT 1 Trial

Lawrence Wechsler, M.D., University of Pittsburgh Medical Center, Pittsburgh

Embargoed for 11:20 a.m. PT, Wednesday, Feb. 17, 2016 / Presented: 11:44 a.m. PT (Hall K)

Late-breaking Science Oral Abstracts I

LB3. ARTSS-2: Final Results of a Pilot, Phase IIb, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke

Andrew Barreto, University of Texas Health Science Center at Houston, Houston, TX

Embargoed for 3:30 p.m.PT, Wednesday, Feb. 17, 2016 / Presented: 3:30p.m.PT (Room 408)

LB4. ICTuS-2 Final Results

Patrick Lyden, Cedars-Sinai Medical Ctr, Los Angeles, CA

Embargoed for 3:30 p.m.PT, Wednesday, Feb. 17, 2016/ Presented: 3:42 p.m. PT (Room 408)

LB5. High-dose Statin Therapy After Acute Ischemic Stroke: The Phase 2 Neuroprotection with Statin Therapy

Mitchell S. Elkind, Columbia Univ, New York, NY

Embargoed for 3:30 p.m.PT, Wednesday, Feb. 17, 2016/ Presented: 3:54p.m. PT (Room 408)

LB6. GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study Toward Preventing Edema After Ischemia

Kevin N. Sheth, Yale Univ, New Haven, CT

Embargoed for 3:30 p.m.PT, Wednesday, Feb. 17, 2016/ Presented: 4:06p.m. PT (Room 408)

LB7. Time is Brain in Endovascular Thrombectomy: Results From Individual Patient Pooled Data Analysis of Mr Clean, Escape, Extend IA, Swift Prime and Revascat

Michael D. Hill, Univ of Calgary, Calgary, Canada

Embargoed for 3:30 p.m.PT, Wednesday, Feb. 17, 2016/ Presented: 4:18p.m. PT (Room 408)

LB8. Virtual Reality in Stroke Rehabilitation: Results From EVREST Multicenter Trial

Gustavo Saposnik, Center for Virtual Reality Studies, St Michael's Hospital, University of Toronto, Canada

Embargoed for 3:30 p.m.PT, Wednesday, Feb. 17, 2016 / Presented: 4:30p.m. PT(Room 408)

LB9. Results of the Pragmatic Ischaemic Thrombectomy Evaluation (PISTE) Trial

Keith W. Muir, Univ of Glasgow, Glasgow, United Kingdom

Embargoed for 3:30 p.m.PT, Wednesday, Feb. 17, 2016 / Presented: 4:42p.m. PT (Room 408)

Plenary Session II

LB10. Carotid Endarterectomy versus Stenting for Treatment of Carotid Artery Stenosis: Long-term Results of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST)

Thomas G Brott, Mayo Clinic Jacksonville, Jacksonville, FL.
Embargoed for 11 a.m. PT, Thursday, Feb. 18, 2016 / Presented: 11:00 a.m. PT(Hall K)

LB11. A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA): 5-year Results

Christian Stapf, University of Montréal - CRCHUM, Montreal, QC, Canada

Embargoed for 11 a.m. PT, Thursday, Feb. 18, 2016 / Presented: 11:12 a.m. PT(Hall K)

LB12. Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III) Results

Daniel F Hanley, Johns Hopkins Univ, Baltimore, MD; CLEAR III Investigators

Embargoed for 11a.m. PT, Thursday, Feb. 18, 2016 / Presented: 11:24 a.m. PT (Hall K)

LB13. Efficiency of Intraventricular Hemorrhage Removal Determines Modified Rankin Scale Score (CLEAR III)

Issam A Awad, Univ of Chicago, Chicago, IL; CLEAR III Investigators

Embargoed for 11 a.m. PT, Thursday, Feb. 18, 2016 / Presented: 11:36 a.m. PT(Hall K)

LB14. Randomized Trial on Normalization of International Normalized Ratio Using Prothrombin Complex or Fresh Frozen Plasma in Vitamin-k Related Intracranial Bleeding

Thorsten Steiner, Klinikum Frankfurt Höchst, Frankfurt, Germany

Embargoed for 11 a.m. PT, Thursday, Feb. 18, 2016 / Presented: 11:48 a.m. PT(Hall K)

Late-breaking Science Oral Abstracts II

LB15. Predictors of Intracranial Hemorrhage and Clinical Outcome After Stentriever Thrombectomy: Pooled Analysis From Swift Prime, Swift and Star Trials

Radoslav Raychev, UCLA Stroke Ctr, Los Angeles, CA

Embargoed for 1:30p.m. PT, Thursday, Feb. 18, 2016 / Presented: 1:30 p.m. PT (Room 408)

LB16. Randomized Trial of Revascularization with Solitaire FR® dDevice versus Best Medical Therapy in the Treatment of Acute Stroke due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset) REVASCAT Trial- Final Results at 12 Months

Antoni Davalos, Hospital Germans Trias y Pujol, Barcelona, Spain

Embargoed for 1:30p.m. PT, Thursday, Feb. 18, 2016 / Presented: 1:42 p.m. PT (Room 408)

LB17. Expanding Opportunities for Intravenous Alteplase Treatment of Patients With Unwitnessed Acute Stroke Using MRI-based Patient Selection: Imaging Results of the MR WITNESS Multicenter Trial (NCT01282242)

Ona Wu, Massachusetts General Hospital, Boston, MA

Embargoed for 1:30p.m. PT, Thursday, Feb. 18, 2016 / Presented: 1:54 p.m.PT (Room 408)

LB18. Endovascular Treatment in Acute Ischemic Stroke: A Meta-analysis of Individual Patient Data From Mr Clean, Escape, Extend IA, Swift Prime and Revascat

Tudor G Jovin, UPMC Stroke Inst, Pittsburgh, PA

Embargoed for 1:30p.m. PT, Thursday, Feb. 18, 2016/ Presented: 2:06 p.m. PT (Room 408)

LB19. MultiStem® Treatment Reduces Length of Hospitalization When Administered Within 36 Hours After Onset of Ischemic Stroke: Implications on Lowering Stroke Related Health Care Costs

Lawrence R. Wechsler, University of Pittsburgh Medical Center, Pittsburgh, PA

Embargoed for 1:30p.m. PT, Thursday, Feb. 18, 2016 / Presented: 2:18 p.m.PT (Room 408)

LB20. Validation of a Simplified Eight-item NIHSS to Identify Acute Ischemic Stroke Patients With Large Vessel Occlusion

Jelle Demeestere, John Hunter Hospital, Newcastle, Australia

Embargoed for 1:30 p.m. PT, Thursday, Feb. 18, 2016 / Presented: 2:30 p.m, PT (Room 408)

LB21. Cost-effectiveness of Solitaire + IV-tPA for Acute Ischemic Stroke: Results From the Swift-Prime Trial

Theresa I Shireman, Brown University, Providence, RI

Embargoed for 1:30 p.m. PT, Thursday, Feb. 18, 2016 / Presented: 2:42 p.m.PT (Room 408)

Plenary Session III

LB22. Primary Results of the ACTION Trial of Natalizumab in Acute Ischemic Stroke (AIS)

Jacob Elkins, Biogen, Cambridge, MA

Embargoed for 11:55 a.m. PT, Friday, Feb. 19, 2016 / Presented: 11:53 a.m. PT(Hall K)

LB23. IV Alteplase in MR-selected Patients With Stroke of Unknown Onset is Safe and Feasible: Results of the Multicenter MR WITNESS Trial (NCT01282242)

Lee H. Schwamm, Massachusetts General Hospital, Boston, MA

Embargoed for 11:55 a.m. PT, Friday, Feb. 19, 2016 / Presented: 12:05 p.m. PT(Hall K)

LB24. GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as Proof-of-Concept

W. Taylor Kimberly, Massachusetts General Hospital, Boston, MA

Embargoed for 11:55 a.m. PT, Friday, Feb. 19, 2016 / Presented: 12:17p.m. PT (Hall K)

Posters

LBP1. Pericyte Control of the Microcirculation in Ischemic Brain

Nabil J Alkayed, Oregon Health & Science Univ, Portland, OR

Embargoed for 3 p.m. PT, Wednesday, Feb. 17, 2016 / Presented: 6:15 p.m. PT (Hall H)

LBP2. Dual Antiplatelet Therapy May Decrease 1-year Stroke Recurrence for Patients With Minor Stroke or Transient Ischemic Attack and Intracranial Arterial Stenosis: Subgroup Analysis of CHANCE

Yuehua Pu, Beijing Tiantan Hosp of Capital Medical Univ, Beijing, China

Embargoed for 3 p.m. PT, Wednesday, Feb. 17, 2016 / Presented: 6:15 p.m. PT (Hall H)

LBP3. Kaiser Stroke EXPRESS Program - Expediting the Process of Evaluating & Stopping Stroke

Jeff Klingman, Kaiser Permanente, Walnut Creek, CA